Since Pim1 and c-Myc cooperate to promote the development of lymphoma [16-18] and prostate cancer [19-21,44], targeting both molecules with one drug could dramatically enhance the efficacy of the treatment in cancer patients. Here, MYC is linked to lymphoma.